{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:34:35Z","timestamp":1791912875657,"version":"4.3.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-138819OB-I00"],"award-info":[{"award-number":["PID2022-138819OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["899163"],"award-info":[{"award-number":["899163"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00140"],"award-info":[{"award-number":["PI24\/00140"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.kint.2025.09.033","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:34:16Z","timestamp":1763692456000},"page":"297-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-1071","authenticated-orcid":false,"given":"Manuel","family":"Praga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5187-9906","authenticated-orcid":false,"given":"Teresa","family":"Cavero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-7763","authenticated-orcid":false,"given":"Gema","family":"Fern\u00e1ndez-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Goicoechea de Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.09.033_bib1","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib3","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome","volume":"104","author":"El Karoui","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2025.09.033_bib4","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2025.09.033_bib5","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ehjcvp\/pvy032","article-title":"ESC Council on hypertension position document on the management of hypertensive emergencies","volume":"5","author":"van den Born","year":"2019","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"10.1016\/j.kint.2025.09.033_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/HYPERTENSIONAHA.121.18502","article-title":"Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community","volume":"79","author":"Vasan","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib8","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.119.043337","article-title":"Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC\/AHA high blood pressure guideline","volume":"140","author":"Pandey","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2025.09.033_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.033_bib10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.09.033_bib12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.kint.2024.02.014","article-title":"Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies","volume":"105","author":"Maisons","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0025-7125(16)33889-5","article-title":"Vascular changes in hypertension","volume":"45","author":"McCormack","year":"1961","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.kint.2025.09.033_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.033_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature\u2014identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.kint.2025.09.033_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023397","article-title":"Malignant hypertension: current perspectives and challenges","volume":"11","author":"Boulestreau","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.kint.2025.09.033_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1409212","article-title":"Malignant hypertension: current challenges, prevention strategies, and future perspectives","volume":"11","author":"Tsige","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.kint.2025.09.033_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00004872-199715110-00016","article-title":"Does renal function improve after diagnosis of malignant phase hypertension?","volume":"15","author":"Lip","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"van den Born","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib24","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/01.hjh.0000249710.21146.38","article-title":"Ethnic disparities in the incidence, presentation and complications of malignant hypertension","volume":"24","author":"van den Born","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib26","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/HJH.0000000000001446","article-title":"Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry","volume":"35","author":"Shantsila","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib27","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","article-title":"Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort","volume":"37","author":"Rubin","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib28","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","article-title":"Thrombotic microangiopathy in patients with malignant hypertension","volume":"38","author":"Cavero","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.033_bib29","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jacc.2024.02.037","article-title":"Malignant hypertension: a systemic cardiovascular disease: JACC review topic of the week","volume":"83","author":"Boulestreau","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2025.09.033_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ckj\/sfu116","article-title":"Malignant hypertension with thrombotic microangiopathy and persistent acute kidney injury (AKI)","volume":"7","author":"Nzerue","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.09.033_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5414\/CNP73147","article-title":"Severe renal failure and microangiopathic hemolysis induced by malignant hypertension\u2014case series and review of literature","volume":"73","author":"Shavit","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib32","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/HJH.0000000000003851","article-title":"Baseline characteristics of the first 302 patients included for acute malignant hypertension crisis in the prospective multidisciplinary HAMA cohort","volume":"42","author":"Boulestreau","year":"2024","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib33","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","article-title":"Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics","volume":"27","author":"Geerdink","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00467-014-2975-4","article-title":"Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension","volume":"30","author":"Ohta","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ccr3.59","article-title":"How atypical can atypical hemolytic uremic syndrome be?","volume":"2","author":"Sajan","year":"2014","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.kint.2025.09.033_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2023.12.021","article-title":"Hot spot of complement factor I rare variant p.Ile357Met in patients with hemolytic uremic syndrome","volume":"84","author":"Schwotzer","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.033_bib37","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40620-022-01465-z","article-title":"Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry","volume":"36","author":"Halimi","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib38","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1093\/ndt\/gfq143","article-title":"Long-term renal survival in malignant hypertension","volume":"25","author":"Gonz\u00e1lez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.033_bib39","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ajh.2009.153","article-title":"Improving survival of malignant hypertension patients over 40 years","volume":"22","author":"Lane","year":"2009","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2015.112","article-title":"From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency","volume":"30","author":"Cremer","year":"2016","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41440-020-0521-2","article-title":"Concurrent analogous organ damage in the brain, eyes, and kidneys in malignant hypertension: reversible encephalopathy, serous retinal detachment, and proteinuria","volume":"44","author":"Mishima","year":"2021","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2025.09.033_bib42","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1097\/HJH.0000000000002950","article-title":"Neurologically asymptomatic patients frequently present cerebral injuries during malignant hypertension: a MRI study","volume":"39","author":"Boulestreau","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib43","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ekir.2022.02.002","article-title":"Comparison of complement pathway activation in autoimmune glomerulonephritis","volume":"7","author":"Genest","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.09.033_bib44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1152\/ajplegacy.1976.230.3.849","article-title":"Effects of saline drinking on malignant course of renal hypertension in rats","volume":"230","author":"M\u00f6hring","year":"1976","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2025.09.033_bib45","doi-asserted-by":"crossref","first-page":"I177","DOI":"10.1161\/01.HYP.6.2_Pt_2.I177","article-title":"Malignant hypertensive crisis induced by chronic intrarenal norepinephrine infusion","volume":"6","author":"Lohmeier","year":"1984","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib46","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.amjhyper.2007.02.018","article-title":"The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension","volume":"20","author":"van den Born","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.35.2.587","article-title":"Blood pressure-independent effects in rats with human renin and angiotensinogen genes","volume":"35","author":"Mervaala","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib48","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00004872-199816050-00011","article-title":"Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27","volume":"16","author":"Montgomery","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib49","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCRESAHA.117.312153","article-title":"Deficiency of complement C3a and C5a receptors prevents angiotensin II-induced hypertension via regulatory T cells","volume":"122","author":"Chen","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2025.09.033_bib50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ajh\/hpt274","article-title":"Antagonist of C5aR prevents cardiac remodeling in angiotensin II-induced hypertension","volume":"27","author":"Zhang","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib51","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/ATVBAHA.113.303120","article-title":"Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling","volume":"34","author":"Zhang","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2025.09.033_bib52","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2015050562","article-title":"Immune mechanisms in arterial hypertension","volume":"27","author":"Wenzel","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib54","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","article-title":"Secondary atypical hemolytic uremic syndromes in the era of complement blockade","volume":"95","author":"Praga","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib55","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.kint.2019.07.006","article-title":"Complement inhibitors are useful in secondary hemolytic uremic syndromes","volume":"96","author":"Caravaca-Fontan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib56","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.033_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.09.033_bib58","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/S2214-109X(14)70002-6","article-title":"The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis","volume":"2","author":"Stanifer","year":"2014","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.kint.2025.09.033_bib59","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/HYPERTENSIONAHA.115.05241","article-title":"Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States","volume":"65","author":"Polgreen","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00004872-199508000-00013","article-title":"Complications and survival of 315 patients with malignant-phase hypertension","volume":"13","author":"Lip","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib61","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.HYP.0000024349.85680.87","article-title":"Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt","volume":"40","author":"Price","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib63","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5414\/CNP66397","article-title":"A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy","volume":"66","author":"Chang","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib64","first-page":"1","article-title":"Malignant or accelerated hypertension in IgA nephropathy","volume":"27","author":"Sub\u00edas","year":"1987","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000090058","article-title":"Malignant hypertension in patients with idiopathic IgA nephropathy","volume":"28","author":"Chen","year":"2005","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2025.09.033_bib66","first-page":"1211","article-title":"Malignant hypertension: aetiology and outcome in 83 patients","volume":"8","author":"Yu","year":"1986","journal-title":"Clin Exp Hypertens A"},{"key":"10.1016\/j.kint.2025.09.033_bib67","article-title":"Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy","volume":"15","author":"Neves PDM de M","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.09.033_bib68","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/ndt\/gfz241","article-title":"Glomerular endothelial activation, C4d deposits and microangiopathy in immunoglobulin A nephropathy","volume":"36","author":"Trimarchi","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.033_bib69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2019.03.416","article-title":"Microangiopathic lesions in IgA nephropathy: a cohort study","volume":"74","author":"Cai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.033_bib70","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.09.033_bib71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2025.09.033_bib72","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ekir.2022.03.028","article-title":"The role of complement in microangiopathic lesions of IgA nephropathy","volume":"7","author":"Li","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.09.033_bib73","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1053\/j.ajkd.2020.03.017","article-title":"Arteriolar C4d in IgA nephropathy: a cohort study","volume":"76","author":"Faria","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.033_bib74","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41379-019-0259-z","article-title":"Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis","volume":"32","author":"Chua","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2025.09.033_bib75","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H\u2013related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib76","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.kint.2017.03.041","article-title":"Elevated factor H\u2013related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy","volume":"92","author":"Tortajada","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.033_bib77","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000485194","article-title":"Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: a case report successfully treated with eculizumab","volume":"138","author":"Nakamura","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2025.09.033_bib78","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.033_bib79","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib80","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/path.1711030306","article-title":"Vascular lesions of malignant essential hypertension","volume":"103","author":"Sanerkin","year":"1971","journal-title":"J Pathol"},{"key":"10.1016\/j.kint.2025.09.033_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1161\/01.RES.36.6.133","article-title":"Malignant hypertension due to musculo-mucoid intimal hyperplasia of intrarenal arteries. Absence of renal fibrinoid necrosis","volume":"36","author":"Pitcock","year":"1975","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2025.09.033_bib82","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/680502","article-title":"Clinical and renal biopsy findings predicting outcome in renal thrombotic microangiopathy: a large cohort study from a single institute in China","volume":"2014","author":"Yu","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.kint.2025.09.033_bib83","first-page":"1","article-title":"Clinico-histological features of thrombotic microangiopathy in renal biopsies: a retrospective study","volume":"38","author":"Manickam","year":"2022","journal-title":"Turk Patoloji Derg"},{"key":"10.1016\/j.kint.2025.09.033_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12882-016-0254-2","article-title":"Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study","volume":"17","author":"Liang","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib85","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/ndt\/gfac324","article-title":"Nephrosclerosis in young patients with malignant hypertension","volume":"38","author":"Bureau","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.033_bib86","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ndt\/gfaa280","article-title":"Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis","volume":"36","author":"Zhang","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.033_bib87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2169\/internalmedicine.52.7398","article-title":"Clinical and pathological evaluation of hypertensive emergency-related nephropathy","volume":"52","author":"Nonaka","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.kint.2025.09.033_bib88","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4103\/ijn.IJN_332_19","article-title":"A 10-year study: renal outcomes in patients with accelerated hypertension and renal dysfunction","volume":"30","author":"Anitha","year":"2020","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib89","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/jch.13848","article-title":"Clinical value of multiorgan damage in hypertensive crises: a prospective follow-up study","volume":"22","author":"Ma","year":"2020","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.kint.2025.09.033_bib90","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/modpathol.2017.154","article-title":"Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy","volume":"31","author":"Larsen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2025.09.033_bib91","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.09.033_bib92","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00467-022-05451-2","article-title":"Systematic review of atypical hemolytic uremic syndrome biomarkers","volume":"37","author":"Raina","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib93","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.09.033_bib94","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2025.09.033_bib95","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ekir.2021.01.034","article-title":"Functional and genetic landscape of complement dysregulation along the spectrum of thrombotic microangiopathy and its potential implications on clinical outcomes","volume":"6","author":"Timmermans","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.09.033_bib96","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ekir.2023.10.003","article-title":"Ex vivo test of complement dysregulation in atypical hemolytic uremic syndrome kidney transplant patients: a pilot study","volume":"9","author":"Duineveld","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.09.033_bib98","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood.2022017860","article-title":"How I diagnose and treat atypical hemolytic uremic syndrome","volume":"141","author":"Fakhouri","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.09.033_bib99","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.09.033_bib100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:04:11Z","timestamp":1781456651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825008798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0085253825008798"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.033","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}